RVMD Q2 2024 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$157M

Net Income

-$133M

EPS (Diluted)

$-0.81

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$128M

Free Cash Flow

-$131M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$190M

Stockholders' Equity

$1.6B

Cash & Equivalents

$276M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$4M	-100.0%
Gross Profit	$0	$4M	-100.0%
Operating Income	-$157M	-$109M	-44.0%
Net Income	-$133M	-$98M	-35.5%